Skip to main content
Top
Published in: Journal of Endocrinological Investigation 9/2016

01-09-2016 | Original Article

Prevalence of overweight/obesity, abdominal obesity and metabolic syndrome and atypical cardiometabolic phenotypes in the adult Romanian population: PREDATORR study

Authors: S. Popa, M. Moţa, A. Popa, E. Moţa, C. Serafinceanu, C. Guja, D. Catrinoiu, N. Hâncu, R. Lichiardopol, C. Bala, A. Popa, G. Roman, G. Radulian, R. Timar, B. Mihai

Published in: Journal of Endocrinological Investigation | Issue 9/2016

Login to get access

Abstract

Purpose

The objectives were to assess the prevalence of overweight/obesity, abdominal obesity and metabolic syndrome (MetS), and to evaluate the characteristics of the metabolically unhealthy lean (MUHL) and metabolically healthy overweight/obese (MHO) phenotypes in a Romanian population-based sample from the PREDATORR study.

Methods

PREDATORR was an epidemiological study with a stratified, cross-sectional, cluster random sampling design. Participants were classified into four cardiometabolic phenotypes based on the BMI, the cut-off value being 25 kg/m2, and the presence of MetS (defined according to the Harmonization definition 2009): MUHL, MHO, metabolically healthy lean (MHL) and metabolically unhealthy overweight/obese (MUHO).

Results

Overall, 2681 subjects aged 20–79 years were included in the analysis. The overall age and sex-adjusted prevalence of obesity was 31.90 %, overweight was 34.7 %, abdominal obesity was 73.90 % and MetS was 38.50 %. The age- and sex-adjusted prevalence of MHO phenotype was 31.60 %, while MUHL phenotype prevalence was 3.90 %. MUHL and MHO participants had a cardiometabolic profile, kidney function and CVD risk intermediary between MHL and MUHO. MUHL had higher odds of being associated with CVD risk (OR 5.8; p < 0.001), abdominal obesity, prediabetes, diabetes, hypertriglyceridemia and hypo-HDL cholesterolemia than MHL, while MHO phenotype was associated with hypo-HDL cholesterolemia (OR 3.1; p = 0.002), prediabetes (OR 2.9; p < 0.001) and abdominal obesity.

Conclusions

PREDATORR study showed a high prevalence of obesity/overweight, abdominal obesity and MetS in the adult Romanian population, and their association with kidney function and several cardiometabolic factors.
Literature
6.
go back to reference Cinteza M, Pana B, Cochino E et al (2007) Prevalence and control of cardiovascular risk factors in Romania cardio-zone national study. Mædica J Clin Med 2(4):277–282 Cinteza M, Pana B, Cochino E et al (2007) Prevalence and control of cardiovascular risk factors in Romania cardio-zone national study. Mædica J Clin Med 2(4):277–282
7.
go back to reference Dorobantu M, Badila E, Ghiorghe S et al (2008) Total cardiovascular risk estimation in Romania. Data from the SEPHAR study. Rom J Intern Med 46(1):29–37PubMed Dorobantu M, Badila E, Ghiorghe S et al (2008) Total cardiovascular risk estimation in Romania. Data from the SEPHAR study. Rom J Intern Med 46(1):29–37PubMed
8.
go back to reference Motamed N, Razmjou S, Hemmasi G, et al (2015) Lipid accumulation product and metabolic syndrome: a population-based study in northern Iran, Amol. J Endocrinol Invest [Epub ahead of print] Motamed N, Razmjou S, Hemmasi G, et al (2015) Lipid accumulation product and metabolic syndrome: a population-based study in northern Iran, Amol. J Endocrinol Invest [Epub ahead of print]
10.
go back to reference de Luis DA, Aller R, Izaola O et al (2014) Cardiovascular risk factors and adipocytokines levels after two hypocaloric diets with different fat distribution in obese subjects and rs6923761 gene variant of glucagon-like peptide 1 receptor. J Endocrinol Invest 37(9):853–859. doi:10.1007/s40618-014-0116-3 CrossRefPubMed de Luis DA, Aller R, Izaola O et al (2014) Cardiovascular risk factors and adipocytokines levels after two hypocaloric diets with different fat distribution in obese subjects and rs6923761 gene variant of glucagon-like peptide 1 receptor. J Endocrinol Invest 37(9):853–859. doi:10.​1007/​s40618-014-0116-3 CrossRefPubMed
13.
go back to reference Wildman RP, Muntner P, Reynolds K et al (2008) The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 168(15):1617–1624. doi:10.1001/archinte.168.15.1617 CrossRefPubMed Wildman RP, Muntner P, Reynolds K et al (2008) The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 168(15):1617–1624. doi:10.​1001/​archinte.​168.​15.​1617 CrossRefPubMed
15.
16.
go back to reference Meigs JB, Wilson PW, Fox CS et al (2006) Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91(8):2906–2912CrossRefPubMed Meigs JB, Wilson PW, Fox CS et al (2006) Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91(8):2906–2912CrossRefPubMed
17.
20.
21.
go back to reference Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645. doi:10.1161/CIRCULATIONAHA.109.192644 CrossRefPubMed Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645. doi:10.​1161/​CIRCULATIONAHA.​109.​192644 CrossRefPubMed
22.
go back to reference Matthews D, Hosker J, Rudenski A et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRefPubMed Matthews D, Hosker J, Rudenski A et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRefPubMed
23.
24.
go back to reference Cleeman J, Grundy S, Becker D et al (2001) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III). JAMA 285:2486–2497CrossRef Cleeman J, Grundy S, Becker D et al (2001) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III). JAMA 285:2486–2497CrossRef
25.
go back to reference Kdigo, CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3(1):1–150CrossRef Kdigo, CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3(1):1–150CrossRef
28.
go back to reference Balkau B, Deanfield JE, Després JP et al (2007) International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 116(17):1942–1951CrossRefPubMedPubMedCentral Balkau B, Deanfield JE, Després JP et al (2007) International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 116(17):1942–1951CrossRefPubMedPubMedCentral
31.
34.
go back to reference Chen S, Zhou S, Wu B et al (2014) Association between metabolically unhealthy overweight/obesity and chronic kidney disease: the role of inflammation. Diabetes Metab 40(6):423–430CrossRefPubMed Chen S, Zhou S, Wu B et al (2014) Association between metabolically unhealthy overweight/obesity and chronic kidney disease: the role of inflammation. Diabetes Metab 40(6):423–430CrossRefPubMed
37.
go back to reference Eshtiaghi R, Keihani S, Hosseinpanah F et al (2015) Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: the Tehran Lipid and Glucose Study. Int J Obes (Lond) 39(3):514–519. doi:10.1038/ijo.2014.176 CrossRef Eshtiaghi R, Keihani S, Hosseinpanah F et al (2015) Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: the Tehran Lipid and Glucose Study. Int J Obes (Lond) 39(3):514–519. doi:10.​1038/​ijo.​2014.​176 CrossRef
Metadata
Title
Prevalence of overweight/obesity, abdominal obesity and metabolic syndrome and atypical cardiometabolic phenotypes in the adult Romanian population: PREDATORR study
Authors
S. Popa
M. Moţa
A. Popa
E. Moţa
C. Serafinceanu
C. Guja
D. Catrinoiu
N. Hâncu
R. Lichiardopol
C. Bala
A. Popa
G. Roman
G. Radulian
R. Timar
B. Mihai
Publication date
01-09-2016
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 9/2016
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-016-0470-4

Other articles of this Issue 9/2016

Journal of Endocrinological Investigation 9/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.